Chronos Archive seal

Review checklist: Pablo Neruda (HR-ML051)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the low-volume classification on conventional imaging with a concordant PSMA PET/CT, apalutamide rather than abiraterone or enzalutamide, no docetaxel, radiotherapy to the prostate, apalutamide started one week before leuprolide for flare protection, denosumab at the osteoporosis dose rather than a bone agent for skeletal events, the amlodipine interaction, the grade 2 rash managed without stopping apalutamide, and the missed baseline TSH.
provenance reviewnot_startedSources: the Nobel Prize biography, the Library of the National Congress of Chile, the National Library of Chile (Memoria Chilena), and AP, AFP, CBS, Smithsonian, Globe and Mail and NPR reporting on the forensic investigations. The Fundación Pablo Neruda pages, the New York Times and The Guardian were not read. The posting to France is dated January 1971, not 1970.
safe messaging reviewnot_startedThe dispute over his death is recorded as R disputed, taking no side. No relative or other real person is named in the modern episode or given a statement, decision or health fact; relatives quoted in the news reports are not used. Mood screening is synthetic and below the thresholds for a safety assessment.

Judgment calls (dossier editorial resolutions)

  1. Sources. The history rests on the Nobel Prize biography, the Library of the National Congress of Chile, the National Library of Chile (Memoria Chilena), and AP, AFP, CBS, Smithsonian, Globe and Mail and NPR reporting on the forensic investigations. The Fundación Pablo Neruda biography page was fetched but its text did not load and is not cited; the New York Times (paywalled) and The Guardian were not read; the 2023 panel's own report was not read, only reporting on it. Britannica returned an error. Wikipedia was not used.
  2. Recent-death rule. He died in 1973, so the rule does not apply; a sick visit is included.
  3. Ambassador dates (correction to the brief). The brief gave the posting to France as 1970 to 1972. The sources say he was named after the 1970 election, the Senate approved the appointment on 21 January 1971, he presented credentials at the end of January 1971, and he resigned and returned to Chile in November 1972. The record uses 1971 to 1972 (CLM-0004).
  4. Prostate cancer in 1971. Only the congressional biography dates it: health problems from July 1971 and an operation for prostate cancer, with convalescence in France (CLM-0005, certainty “probable”). Paris is not named as the place of the operation, and the type of operation, the stage, the grade and any hormone treatment are not recorded in the sources read; the record invents none of them for the history.
  5. Cause of death and the poisoning dispute. The death certificate's cause (cancer cachexia) is recorded as a documented statement (CLM-0008). The 2013 tests, the 2017 panel, the 2023 Clostridium botulinum finding and the 2024 reopening are each recorded as reported (CLM-0009 to CLM-0012). Whether he died of cancer, of another natural cause or of poisoning is recorded as R, certainty “disputed” (CLM-0013), taking no side. The modern episode is set two years before his death and does not foreshadow it.
  6. Name and alias. The display name is the pen name he made legal in 1946. The alias is the congressional biography's birth name, Ricardo Eliecer Neftalí Reyes Basoalto, which appears in no other record; the Nobel biography orders the given names differently (Neftalí Ricardo), and the brief's accented “Eliécer” was not found in a source read. identity.name_parts is not used because the display name splits simply. The notes call him Mr. Neruda, as the modern episode records he asked.
  7. Living people and relatives. No living person is named. His nephew, his driver, judges and scientists quoted in the news reports are not named and nothing they said is used beyond the scientists' findings. His mother appears only in the documented family history; his wife in the modern episode is unnamed, has no role in his care and is not a source of history; his health care agent is unnamed. No other figure with a record is named, so identity.historical_mentions is not used.
  8. Index age and dates. The index visit on June 1, 2026 maps to June 1, 1971, when he was 66 and ambassador in France, weeks before the health problems of July 1971. The synthetic date of birth is 1959-07-12, a shift of 55 years. The visits on June 15, July 13, August 10, September 14 and October 5, 2026 map to the same days of 1971, before the Nobel Prize was announced on October 21, 1971; he turns 67 before the third visit. The presenting pattern is urinary symptoms and bone pain with a raised PSA, recorded as a resolved problem (R97.20) at the second visit, when the diagnosis is made.
  9. Care setting. The true frame is Paris. The modern episode keeps the project's U.S. conventions: St. Posthumous Health Center, U.S. coding, and a Medicare-style annual wellness visit; his coverage is described as an international plan through his country's diplomatic service. He is cared for in Spanish, his first language, through a professional medical interpreter, with written plans in Spanish, without any claim about Chilean or Latin American patients in general.
  10. Extent of disease (decision). Metastatic hormone-sensitive prostate cancer, de novo, low volume: two bone metastases (right ilium and L5) and two pelvic nodes, no visceral disease, on CT and bone scan, with a concordant PSMA PET/CT. Chosen because bone pain with a raised PSA fits metastatic disease, and low volume lets the record teach radiotherapy to the prostate and the decision against docetaxel. High-volume disease was considered and not chosen.
  11. Treatment choices. (1) Leuprolide continuously, with apalutamide 240 mg daily started one week earlier to cover the testosterone flare (AUA statement 18 discourages first-generation antiandrogens except for flare). (2) Apalutamide rather than abiraterone (needs prednisone; hypertension and prediabetes) or enzalutamide (a reasonable alternative). (3) No docetaxel in low-volume disease (CHAARTED; AUA statement 16 limits triplets to select patients). (4) Radiotherapy to the prostate, 55 Gy in 20 fractions (STAMPEDE). (5) Germline and somatic testing, both negative (synthetic).
  12. Bone-modifying agent (correction to the brief). The brief asked for a bone-modifying agent for metastases. In hormone-sensitive disease the AUA/SUO guideline recommends denosumab or zoledronic acid at the skeletal-event doses only for castration-resistant disease with bone metastases (statement 40), and early zoledronic acid did not reduce skeletal events in CALGB 90202. The record gives denosumab 60 mg every six months, the osteoporosis dose, for his own fracture risk (FRAX hip 3.4 percent with androgen deprivation counted; AUA statement 39; CMID threshold 3 percent), after a dental examination.
  13. Guideline name (correction to the brief). The brief named an AUA/ASTRO/SUO 2023 advanced prostate cancer guideline. The 2023 amendment is titled AUA/SUO (Lowrance 2023, PMID 37096583); the AUA page now shows a 2026 amendment. Both are cited.
  14. Protocol deviation. A TSH before apalutamide was ordered at the second visit but not drawn because it was left off the laboratory requisition. The first TSH, four weeks into treatment, was normal (2.4 mIU/L); at three months it was 5.4 mIU/L with a normal free T4, so the change is attributed to apalutamide, but a true baseline was lost. Corrective action: TSH added to the apalutamide start checklist.
  15. Synthetic clinical picture. Everything in the modern episode is synthetic: the symptoms, hypertension and prediabetes, every laboratory value, the imaging, the biopsy, DXA and FRAX, the genetic results, the scores (PHQ-9, PHQ-2, IPSS, pain, Mini-Cog, AUDIT-C), medicines and outcomes. Height (178 cm) and weights (BMI about 29 to 30) are synthetic; the 2017 panel's remark that he was obese at death was not used to set them. Reference ranges are typical adult male ranges.
  16. Sick visit. A grade 2 maculopapular rash from apalutamide eight weeks into treatment, during radiotherapy (L27.0), managed with topical triamcinolone and cetirizine while apalutamide continued, as the label allows; severe reactions were excluded by examination, eosinophils and liver tests. Chosen because it follows from his treatment and insinuates no undocumented diagnosis.
  17. Annual wellness visit. A subsequent annual wellness visit at 67 (HCPCS G0439 and CPT 99497 in plain text). Judgment calls: high-dose influenza, COVID-19 and PCV20 that day, zoster deferred at his request; RSV not given (under 75 without a qualifying condition; prostate cancer on androgen deprivation was not counted as one, a point the owner may review); atorvastatin 20 mg for a pooled-cohort risk of about 17 percent; advance care planning in Spanish with an unnamed agent.
  18. Focused visits. The three chronic-care follow-ups (the consultation day, four weeks, and three months) are documented as focused visits on the CMID prostate cancer monograph, NCCN, the AUA/SUO guideline and the apalutamide label. Synthetic findings introduced: the early PSA fall to 6.2 and the three-month PSA of 0.18 ng/mL, castrate testosterone, a blood pressure rise on apalutamide treated by raising amlodipine to 10 mg, the raised TSH, mild anemia, A1c rising to 6.1 percent, and grade 1 radiotherapy effects. The one deviation is the missed baseline TSH above.
  19. Consultation. The genitourinary medical oncology referral and the consultation by Étienne Okonkwo-Lund, MD (a fictional consultant), on the day of the second visit, are S. The consultant answers the six referral questions in line with what the record shows afterwards: low-volume de novo mHSPC; apalutamide with leuprolide and no docetaxel; radiotherapy to the prostate; denosumab at the osteoporosis dose for fracture risk, not for skeletal events; germline and somatic testing; and the amlodipine interaction with a monitoring plan for primary care.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-07-13
Progress note 03 (C-CDA)
Baseline TSH before apalutamide missedBefore starting apalutamideOrdered at the last visit but not drawn, a deviation from the protocol: the order was not on the laboratory requisition sent with the germline sample. Today's value is normal, so a pre-existing thyroid problem is unlikely and no harm has resulted, but a true baseline is lost. Corrective action: the apalutamide start checklist now includes TSH, drawn with the first prescription

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-06-15
Progress note 02 (C-CDA)
LaboratoryTSH before apalutamideOrderedOrdered today before the first dose
2026-06-15
Progress note 02 (C-CDA)
ReferralRadiation oncology for radiotherapy to the prostateOrderedPlanning visit in about four weeks
2026-07-13
Progress note 03 (C-CDA)
ReferralSomatic tumor testingOrderedSent on the biopsy tissue; pending
2026-07-13
Progress note 03 (C-CDA)
ReferralRadiotherapy to the prostateOrderedPlanning done; 20 fractions start in two weeks

Evidence to check

Retrospective claims (R)

ClaimStatementCertainty
CLM-0013Whether he died of his prostate cancer, of another natural cause such as an infection, or of poisoning is disputed and unresolved. The death certificate gives cancer cachexia; the 2013 tests found no relevant chemical substances; the 2017 panel rejected cachexia without naming a cause; the 2023 finding of Clostridium botulinum could not show how it got there; and the investigation was reopened in 2024.disputed

Sensitive claims

None.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-06-01PSA46.8 ng/mL (high)High
2026-06-01Glucose104 mg/dL (high)High
2026-06-01Alkaline phosphatase168 U/L (high)High
2026-06-01Hemoglobin A1c5.9% (high)High
2026-06-01Total cholesterol214 mg/dL (high)High
2026-06-01LDL cholesterol140 mg/dL (high)High
2026-06-0125-hydroxyvitamin D22 ng/mL (low)Low
2026-06-15Femoral neck T-score (DXA)-2.1 (low)Low
2026-06-15Lumbar spine T-score, L1 to L4 (DXA)-1.4 (low)Low
2026-07-13PSA6.2 ng/mL (high)High
2026-07-13Total testosterone22 ng/dL (low)Low
2026-07-13Glucose101 mg/dL (high)High
2026-07-13Alkaline phosphatase141 U/L (high)High
2026-07-1325-hydroxyvitamin D28 ng/mL (low)Low
2026-09-14Total testosterone14 ng/dL (low)Low
2026-09-14Hemoglobin12.9 g/dL (low)Low
2026-09-14Glucose102 mg/dL (high)High
2026-09-14TSH5.4 mIU/L (high)High
2026-09-14Hemoglobin A1c6.1% (high)High